|
PCSK9 inhibitor arilocumab lowers cholesterol and cardiovascular events |
 |
 |
|
European Society of Cardiology: At the European Society of Cardiology’s annual meeting in Barcelona, experts revealed that the drug alirocumab was effective in lowering the so-called bad cholesterol within weeks. The effect was even greater in a combination with statin treatment. The promising findings come from an interim safety analysis of one of the nine studies reported in July to have shown consistent LDL reductions. The analysis indicates that patients given alirocumab were less likely to suffer cardiovascular events, such as cardiac death, heart attack, stroke and chest pain requiring hospitalization.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
